Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

Research & Analysis: ERock, Inc. (NYSE: EROC)

ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity through early 2028.

EROC $453M
Monte Independent Investment Research 7 clicks

From X

@StableBread

Fajasy on X

Q2 2026 was the first quarter of positive FCF at Magna Mining $MGMNF (TSX: $NICU), but only because cash from March sales arrived in April. The quarter set Magna-era records for revenue and cash margin: → Revenue: US$21.5M, after the precious metals stream and higher smelting and refining charges. → Cash margin: Record US$6.4M, or US$1.41/payable lb, up from US$4.3M in Q1. → Operating cash flow: US$6.4M, including US$4.8M of March sales paid in April. → Free cash flow: US$3.7M, even though operating cash flow absorbed US$3.8M of exploration and evaluation spending, mostly at Levack, Magna’s flagship restart project. Adjusted for the US$4.8M of March sales paid in April, Q2 FCF was an outflow of ~US$1.2M, and H1 2026 as a whole was a US$10.5M outflow. At the mine level, McCreedy West (Magna’s producing mine) generated a US$10.8M cash margin in H1 2026, covering its US$3.6M of sustaining capital almost three times over. But Levack, corporate costs, interest, and working capital kept the company as a whole cash-negative. As of June 30, 2026, Magna held US$28.2M of cash. With net proceeds from Alpayana, the Peruvian mining group that bought 19.9% in August, the September deck puts cash at ~US$124M. Magna’s only debt is US$16.9M of unsecured 10% convertible notes due March 5, 2029, a third of which Dundee Corporation $DDEJF, a Toronto investment company, bought. They convert at CAD$2.00/share into 11.98M shares, or 3.8% of the current share count. Magna has funded itself mostly with equity, so the share count rose from 163.4M at the end of 2023 to 313.35M after Alpayana, up 91.8%. Options and share units add more. At June 30, Magna had 12.35M options at a weighted average exercise price of CAD$1.21 and 1.73M restricted and deferred share units. At CAD$2.45, 9.64M of the options are in the money, and exercising them would give Magna ~US$5.1M of cash. Counting the in-the-money options, the share units, and the notes, the diluted count is 336.70M (313.35M + 9.64M + 1.73M + 11.98M).
@calvinblissett 1 click

Calvin Blissett on X

$BBGI diluted 27% (assuming warrants exercised) through that, some asset sales and share sales they generated $19m in cash. It was with an institutional investor. I don’t like getting diluted especially this early. I also don’t like what it implies which is that the liquidity of there assets is not good. There’s a chance this is just evilness by the Beasley family and they are trying to keep the company, the Crown Jewels and fuck shareholders. A more positive read is they think the assets are worth a lot and aren’t being offering competitive prices for them so they chose this instead.

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 31 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $108M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $16M
Atrium Research - Equity Research 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks
PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $103M
Value Investors Club

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…

VICR $8.1B
CV's Substack 28 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 10 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 61 of 249

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.